Evidence map›Paper›PMID 42399672›Full record

ReviewNature medicine2026

Immune aging biomarkers for clinical trials.

Andrea Cipriano, Jamie Justice, Jesse R Poganik, Mahdi Moqri, Omar O Abudayyeh, Jonathan Gootenberg, Laura Haynes, Yotam Levin, Daniel E Martin-Herranz, Arne N Akbar and 13 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Andrea CiprianoDepartment of Obstetrics & Gynecology, Stanford School of Medicine, Stanford University, Stanford, CA, USA. andcip91@stanford.edu.
Jamie JusticeHealth, XPRIZE Foundation, Culver City, CA, USA. jamie.justice@xprize.org.
Jesse R PoganikDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0003-3098-8550
Mahdi MoqriDivision of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6675-0566
Omar O AbudayyehDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jonathan GootenbergDepartment of Stem Cell and Regenerative Biology, Harvard Medical School, Boston, MA, USA.
Laura HaynesUConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0002-5006-3339
Yotam LevinNanoPass Technologies Ltd, Ness Ziona, IL, Israel.
Daniel E Martin-HerranzHurdle.bio/Chronomics Ltd, London, UK.ORCID http://orcid.org/0000-0002-2285-3317
Arne N AkbarDepartment of Aging, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, UK.ORCID http://orcid.org/0000-0002-3763-9380
Joan MannickTornado Therapeutics, New York, USA.
Graham PawelecInstitute of Immunology, University of Tübingen, Tübingen, Germany.ORCID http://orcid.org/0000-0002-3600-0163
Shai S Shen-OrrRuth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.ORCID http://orcid.org/0000-0002-6991-7736
John TsangYale School of Medicine, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3186-3047
Wolfgang WagnerInstitute for Stem Cell Biology, RWTH Aachen University Medical School, Aachen, Germany.ORCID http://orcid.org/0000-0002-1971-3217
Miriam MeradDepartment of Immunology and Immunotherapy, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-4481-7827
Sacha GnjaticDepartment of Immunology and Immunotherapy, Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-5643-9520
Alfred GellhornGlaxoSmithKline, Collegeville, PA, USA.
Michael J CorleyDepartment of Medicine, Division of Geriatrics, Gerontology and Palliative Care, University of California San Diego, San Diego, CA, USA.ORCID http://orcid.org/0000-0001-8957-7153
George A KuchelUConn Center on Aging, University of Connecticut School of Medicine, Farmington, CT, USA.ORCID http://orcid.org/0000-0001-8387-7040
Luigi FerrucciNational Institute on Aging, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-6273-1613
David FurmanBuck AI Platform, Buck Institute for Research on Aging, Novato, CA, USA.ORCID http://orcid.org/0000-0002-3654-9519
Chiara M S HerzogDepartment of Twin Research, Aging and Genetic Epidemiology, Faculty of Life Sciences and Medicine, King's College London, London, UK. ch2151@cam.ac.uk.ORCID http://orcid.org/0000-0002-1572-498X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aging profoundly remodels the immune system, impairing defense, repair and homeostatic function across tissues. Because the immune system operates in every organ, its deterioration has been proposed to drive or exacerbate systemic dysfunction and accelerate overall biological aging, making it an attractive biomarker and target for geroscience-guided trials. Despite this central role, there is no consensus on how to quantify immune aging, especially in clinical trials. Here, we establish a translational framework to identify immune aging biomarkers for this purpose. We define five evaluation criteria for immune aging biomarkers and apply these to candidate biomarkers, discussing their utility in the context of a major international healthspan competition, XPRIZE Healthspan. Metrics encapsulating multidimensional aspects of immune function, inflammaging scores and functional assays performed best against our selection criteria. Finally, we identify promising emerging measures, together with critical gaps that must be addressed to develop reliable, predictive biomarkers of human immune competence. Our framework provides a coherent path toward actionable and clinically meaningful immune aging biomarkers capable of quantifying immune fitness and resilience, and accelerating the clinical translation of geroscience-guided interventions.

Indexed as

AgingBiomarkersClinical Trials as TopicImmune SystemAnimalsGeroscienceHumansBiomarkers

Identifiers

PMID42399672

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.